Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

Nyström, Thomas, Gonon, Adrian T., Sjöholm, Åke, Pernow, John·2005·Regulatory Peptides
DOI 10.1016/j.regpep.2004.08.024

Cited by (187)

Items 101–187 of 187

  1. Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow
    Steven P. Moberly, Zachary C. Berwick, Meredith K. Owen, Mark Svendsen, Kieren J. Mather, Johnathan D. Tune · 2012 · Experimental Biology and Medicine
  2. Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.
    Saumya Kankanala, Rafay M. Syed, Quan Gong, Boxu Ren, Xiaoquan Rao, Jixin Zhong · 2016 · PubMed Central
  3. Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities–the BEGAMI study
    Camilla Hage, Kerstin Brismar, Suad Efendić, Pia Lundman, Lars Rydén, Linda Mellbin · 2013 · Journal of Internal Medicine
  4. Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol
    C. Anholm, Preman Kumarathurai, Malene S Klit, O. P. Kristiansen, O. Nielsen, S. Ladelund, S. Madsbad, A. Sajadieh, S. Haugaard · 2014 · BMJ Open
  5. Potential cardiovascular effects of incretin-based therapies
    Carolyn Fiona Deacon, Nikolaus Marx · 2012 · Expert Review of Cardiovascular Therapy
  6. Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure
    David Nathanson, Mats Frick, Bengt Ullman, Thomas Nyström · 2016 · Diabetology & Metabolic Syndrome
  7. Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes
    Paul S. Jellinger · 2011 · Postgraduate Medicine
  8. Harnessing the incretin system beyond glucose control: Potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes
    Bertrand Cariou · 2012 · Diabetes & Metabolism
  9. Glucagon-like peptide-1 increased the vascular relaxation response via AMPK/Akt signaling in diabetic mice aortas
    Kumiko Taguchi, Nanami Bessho, Nozomu Kaneko, Kanami Okudaira, Takayuki Matsumoto, Tsuneo Kobayashi · 2019 · European Journal of Pharmacology
  10. Cardiovascular and hemodynamic effects of glucagon-like peptide-1
    Adam Glenn Goodwill, Kieren J. Mather, Abass M. Conteh, Daniel Sassoon, Jillian N. Noblet, Johnathan D. Tune · 2014 · Reviews in Endocrine and Metabolic Disorders
  11. Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists
    Baptist Gallwitz · 2009 · The Review of Diabetic Studies
  12. Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient
    Vasilios Kotsis, Jens Jordan, Stella Stabouli, Christina Antza, Dragan Micić, Bojan Jelaković, Markus Peter Schlaich, Peter M. Nilsson, Reinhold Hugo Kreutz, Giuseppe Mancia et al. · 2019 · Journal of Hypertension
  13. Characterization of [125I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta
    Rhoda E. Kuc, Janet J. Maguire, Keith Siew, Sheena Patel, David R. Derksen, V. Margaret Jackson, Kevin M O'Shaughnessey, Anthony P. Davenport · 2014 · Life Sciences
  14. A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes
    Zin Zin Htike, Kamlesh K. Khunti, Melanie Jane Davies · 2012 · Diabetes Therapy
  15. Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?
    William David Strain, Christine Smith · 2016 · Diabetes Therapy
  16. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures
    Julie Rehné Lundgren, Kristine Færch, Daniel R. Witte, Anna Elisabet Jonsson, Oluf Borbye Pedersen, Torben F. Hansen, Torsten Lauritzen, Jens Juul Holst, Dorte Vistisen, Marit E. Jørgensen et al. · 2019 · Cardiovascular Diabetology
  17. Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto–Kakizaki rats
    Lin Wu, Anna Olverling, Liselotte Fransson, Henrik Ortsäter, Camilla Krizhanovskii, Xin Gao, Åke Sjöholm · 2012 · Regulatory Peptides
  18. Glucagon-Like Peptide-1 and its Cardiovascular Effects
    Kyung‐Sun Heo, Keigi Fujiwara, Jun‐ichi Abe · 2012 · Current Atherosclerosis Reports
  19. Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
    Stanley S. Schwartz · 2010 · Diabetes Metabolic Syndrome and Obesity
  20. Correction: Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
    Soo Kyung Lim, Sung Hee Choi, Hayley Shin, Bong Jun Cho, Ho Seon Park, Byung Yong Ahn, Seon Mee Kang, Ji Won Yoon, Hak Chul Jang, Young‐Bum Kim et al. · 2012 · PLoS ONE
  21. Effects of incretin agonists on endothelial nitric oxide synthase expression and nitric oxide synthesis in human coronary artery endothelial cells exposed to TNFα and glycated albumin
    Garczorz, Wojciech, Francuz, Tomasz, Siemianowicz, Krzysztof, Kosowska, Agnieszka, Kłych, Agnieszka, Aghdam, Mohammad Reza F., Jagoda, Krystyna · 2015 · Pharmacological Reports
  22. The Synergistic Effect of Valsartan and LAF237 [(S)-1-[(3-Hydroxy-1-Adamantyl)Ammo]acetyl-2-Cyanopyrrolidine] on Vascular Oxidative Stress and Inflammation in Type 2 Diabetic Mice
    Min Shen, Dongdong Sun, Weijie Li, Bing Liu, Shenxu Wang, Zheng Zhang, Feng Cao · 2012 · Experimental Diabetes Research
  23. GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents
    Qianfeng Xiong, Shao-Hua Fan, Xuewen Li, Yu Niu, Jing Wang, Xin Zhang, Yi-Fan Chen, Yawei Shi, Li-Hui Zhang · 2019 · Cardiology Research and Practice
  24. Insulin Inhibits and Oral Sucrose Increases Neointimal Growth after Arterial Injury in Rats
    Danna M. Breen, Jiwanjeet K. Dhaliwall, Kalam K. Chan, June Guo, Loretta Lam, Michelle Patricia Bendeck, Adria Giacca · 2010 · Journal of Vascular Research
  25. Glucagon-like peptide 1 receptor
    Dieter Hoersch, Joerg Schrader, Ruediger Goeke · 2005 · AfCS-Nature Molecule Pages
  26. Exendin-4 attenuates lipopolysaccharides induced inflammatory response but does not protects H9c2 cells from apoptosis
    Tien‐Hsing Chen, Hung-Ta Wo, Victor Chien‐Chia Wu, Jianliang Wang, Chun‐Chieh Wang, I-Chang Hsieh, Cheng‐Yi Kuo, Chien Ting Liu · 2011 · Immunopharmacology and Immunotoxicology
  27. The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
    Lee, Hae Young, Ko, Seung-Hyun, Park, Sungjoon, Kim, Kyuho, Kim, Song-Yi, Cho, In-Jeong, Cho, Eun Joo, Kim, Hyeon Chang, Park, Jae-Hyeong, Ryu, Sung Kee et al. · 2024 · Clinical Hypertension
  28. Novel role for the incretins in blood pressure regulation
    Preethi Yerram, Adam T. Whaley‐Connell · 2012 · Current Opinion in Nephrology & Hypertension
  29. Glucagon-like peptide-1 accelerates the onset of insulin action on glucose disappearance in mice
    Karl Thomaseth, Alessandra Pavan, Giovanni Pacini, Bo Åhrén · 2007 · American Journal of Physiology-Endocrinology and Metabolism
  30. Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
    Camilla Krizhanovskii, Anders Franco‐Cereceda · 2018 · Current Vascular Pharmacology
  31. Peripheral GLP-1 gastroprotection against ethanol: The role of exendin, NO, CGRP, prostaglandins and blood flow
    Naciye Işbil-Büyükcoşkun, Güldal Güleç Süyen, Betül Çam-Etöz, Kasım Özlük · 2008 · Regulatory Peptides
  32. Effect of peripherally-injected glucagon-like peptide-1 on gastric mucosal blood flow
    Naciye Işbil-Büyükcoşkun, Betül Çam-Etöz, Güldal Güleç Süyen, Kasım Özlük · 2009 · Regulatory Peptides
  33. Effects of incretins on blood pressure: A promising therapy for type 2 diabetes mellitus with hypertension
    Bin Wang, Yinxing Ni, Jian ZHONG, Fang Sun · 2011 · Journal of Diabetes
  34. Effects of Glucagon-like Peptide-1 in Diabetic Rat Small Resistance Arteries
    Zeliha Bayram, Cahit Nacıtarhan, Sadi S. Özdem · 2014 · Journal of Cardiovascular Pharmacology
  35. Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes
    Pyung‐Hwan Kim, Sung Wan Kim · 2012 · ISRN Endocrinology
  36. GLP-1 (7–36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles
    Melissa Chen, Franca S. Angeli, You‐Tang Shen, Richard P. Shannon · 2014 · Cardiovascular Diabetology
  37. Blood Pressure and Cardiovascular Effects of New and Emerging Antidiabetic Agents
    Pelbreton C. Balfour, Carlos J. Rodríguez, Keith C. Ferdinand · 2014 · Current Hypertension Reports
  38. Insulin Resistance and Hypertension
    Sudha S. Shankar, Helmut O. Steinberg · 2012 · Humana Press eBooks
  39. Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide
    Xinyi He, Zimo Zhao, Yan Sun, Xi Jiang · 2025 · European Journal of Medicinal Chemistry
  40. Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
    Stanley S. Schwartz · 2014 · Postgraduate Medicine
  41. Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study
    Sophie J. Clarke, Stephen Pettit, Joel P. Giblett, Tian Xiao Zhao, Anna C. Kydd, Nicolai J. Wewer Albrechtsen, Carolyn Fiona Deacon, Jayan K. Parameshwar, Stephen Paul Hoole · 2018 · Clinical Therapeutics
  42. Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation
    Rufaida Wasim, Tarique Mahmood Ansari, Mohammed Haris Siddiqui, Farogh Ahsan, Arshiya Shamim, Aditya Narayan Singh, Mohammad Shariq, Aamir Anwar, Aquib Rehanullah Siddiqui, Saba Parveen · 2023 · Hormone and Metabolic Research
  43. Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.
    Michael Psallas, C. Manes · 2012 · Europe PMC (PubMed Central)
  44. GLP‐1 modulates insulin‐induced relaxation response through β‐arrestin2 regulation in diabetic mice aortas
    Kumiko Taguchi, Nozomu Kaneko, Kanami Okudaira, Takayuki Matsumoto, Tsuneo Kobayashi · 2020 · Acta Physiologica
  45. Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist
    Signe Vinsand Naver, Espen Jimenez‐Solem, Mikkel Christensen, Jón Trærup Andersen, Filip Krag Knop · 2014 · Clinical Investigation
  46. Effects of nitric oxide synthase inhibition with or without cyclooxygenase‐2 inhibition on resting haemodynamics and responses to exendin‐4
    Sheila Margaret Gardiner, Julie E. March, P.A. Kemp, Thomas M. Bennett · 2006 · British Journal of Pharmacology
  47. Complex vasoactivity of liraglutide. Contribution of three gasotransmitters
    Eszter Sélley, Gergő Attila Molnár, Szilárd Kun, István András Szijártó, Boglárka Laczy, Tibor Kovács, Ferenc Fülöp, István Wittmann · 2015 · Artery Research
  48. Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies
    Paul M. Stranges, Ujjaini Khanderia · 2012 · Therapeutic Advances in Drug Safety
  49. The Effects of DPP4 Inhibitors on Lipid Status and Blood Pressure in Rats with Diabetes Mellitus Type 2
    Stefani S. Bolevich, Nevena D. Draginic, Marijana M. Andjic, Nevena S. Jeremic, Sergey Bolevich, Petr Litvitskiy, Vladimir Lj. Jakovljevic · 2019 · Serbian Journal of Experimental and Clinical Research
  50. Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight
    Masami Tanaka, Hiroshi Itoh · 2025 · Hypertension Research
  51. Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study
    Nikolaos Östlund-Papadogeorgos, Jeanette Kuhl, Angela C. Shore, Thomas Kahan, Gun Jörneskog, Majid Kalani · 2020 · Microcirculation
  52. Chronotropic Responses to GLP-1 Receptor Agonists and Sitagliptin in Atria From Diabetic Rats
    Esra Akcabag, Zinnet Şevval Aksoyalp, Feride Öner, Zeliha Bayram, Gül Özbey, Cahit Nacıtarhan, Sebahat Özdem, Arda Taşatargil, Sadi S. Özdem · 2024 · Journal of Cardiovascular Pharmacology
  53. Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants
    Tanja Vukajlovic, Clara Odilia Sailer, Ali Asmar, Boye Lagerbon Jensen, D. Vogt, Mirjam Christ‐Crain, Bettina Felicitas Winzeler · 2022 · The Journal of Clinical Endocrinology & Metabolism
  54. New and developing pharmacotherapies for hypertension
    Christián Höcht, Miguel Ángel Allo, Ariel Héctor Polizio, Marcela Analia Moretton, Andrea Carranza, Diego A. Chiappetta, Marcelo R. Choi · 2022 · Expert Review of Cardiovascular Therapy
  55. Preventing Flap Necrosis With Adrenomedullin and Glucagon-like Peptide-1.
    Betül Çam Etöz, Naciye Işbil-Büyükcoşkun, Abdullah Etöz, Kasım Özlük · 2012 · PubMed
  56. Glucagon receptor family in GtoPdb v.2023.1
    DOMINIQUE BATAILLE, Susan L.F. Chan, Philippe Delagrange, Daniel J. Drucker, Burkhard Göke, Rebecca Hills, Kelly E. Mayo, Laurence J. Miller, Roberto Salvatori, Bernard Thorens · 2023 · IUPHAR/BPS Guide to Pharmacology CITE
  57. Comparative Study on the Cardiovascular and Pancreatic Effects of Canagliflozin versus Vildagliptin on Experimentally Induced Diabetes and Hypertension in Male Albino Rats
    Tarteel Youssef Hassan Mohamed, Mohamed Abdelhafeez Ahmed, Shireen Sami Mahmoud · 2021 · European Journal of Molecular & Clinical Medicine
  58. The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies
    Dhanwantee Mundil, Mohammad Hossein Noyan-Ashraf, Mansoor Husain · 2010 · Current Cardiovascular Risk Reports
  59. Inkretine: Gibt es kardiovaskuläre Effekte?
    Baptist Gallwitz · 2010 · Herz
  60. Kardiovaskuläre Effekte inkretinbasierter Therapien
    Michael Lehrke, Nikolaus Marx · 2012 · Herz
  61. 277
    Banu Avcioglu Yilmaz, Füsun Baloş Törüner · 2013 · CRC Press eBooks
  62. High Dose of Liraglutide Impairs Renal Function in Female Hypertensive Rats
    Felipe Tonon Firmino, Pollyana Peixoto, Thatiany Jardim Batista, Leonardo da Silva Escouto, Girlândia Alexandre Brasil, Mariana dos Reis Couto, Antônio Ferreira de Melo, Nazaré Souza Bissoli · 2024 · Journal of Cardiovascular Pharmacology
  63. Gut-Derived Hormones—Cardiac Effects of Ghrelin and Glucagon-Like Peptide-1
    Giulia Ruozi, Francesca Bortolotti, Fabio A. Recchia · 2017 · Elsevier eBooks
  64. Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Side Effects
    Rizal Rizal, Suharjono Suharjono · 2021 · Pharmaceutical Journal of Indonesia
  65. Effets cardiovasculaires du GLP-1 : des données expérimentales aux conséquences thérapeutiques des incrétinomimétiques
    C. Halter, P. Böhme, Olivier Ziegler, Bruno Guerci · 2010 · Médecine des Maladies Métaboliques
  66. GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
    Rémy Burcelin, Cendrine Cabou, Chr̀istophe Magnan, Pierre Gourdy · 2011 · Wiley eBooks
  67. Studies on Incretins and Cardiovascular Function
    David Nathanson · 2010 · Figshare
  68. La hipertensión arterial esencial, ¿es esencialmente metabólica?
    Alberto Cordero, José Moreno Arribas, Eduardo Alegría Ezquerra · 2006 · Medicina Clínica
  69. Novye vozmozhnosti v terapii SD 2 tipa: liraglutid - analog chelovecheskogo glyukagonopodobnogo peptida-1
    Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova · 2008 · Diabetes Mellitus
  70. Role of GLP-1 receptor agonists in endothelial function
    Özlem Erdogdu · 2012 · Figshare
  71. Pharmacologic Approach to Type 2 Diabetes in Obese Patients
    León Litwak, Carla Musso, Susana Fuentes · 2014 · Springer eBooks
  72. Papel da dipeptidil peptidase IV na fisiopatologia da insuficiência cardíaca
    Thiago A. Salles · 2016
  73. Efeito do peptídeo-1 semelhante ao glucagon endógeno sobre a atividade do NHE3 em túbulo proximal renal
    Livia Xavier Soares Farah · 2015
  74. Incretinas, Incretinomiméticos, Inhibidores de DPP IV - 1er parte Incretins, Incretinmimetics, Inhibitors
    Claudia Bayón, Barriga Mercedes Araceli, L. Fukushima-Díaz de León · 2010
  75. Glucagon-like peptide-1 alleviating peripheral neuropathy in diabetic patients: advance in mechanism
    Xudong Wen, Wei Tang, Zhimin Liu · 2011 · Academic Journal of Second Military Medical University
  76. Efeito do peptídeo-1 semelhante ao glucagon endógeno sobre a atividade do NHE3 em túbulo proximal renal
    São Paulo, C. Girardi · 2015
  77. Glucagon like peptide-1 (glp-1) in myocardial ischaemia-reperfusion injury.
    Amal Bose · 2006 · OpenGrey (Institut de l'Information Scientifique et Technique)
  78. Abbreviated Title: Extra-Pancreatic Effects of GLP-1
    Rania Abu‐Hamdah, Atoosa Rabiee, Graydon S. Meneilly, Richard P. Shannon, Dariush Elahi · 2009
  79. Incretins, Incretinmimetics, Inhibitors (2 nd part)
    Claudia Bayón, Barriga Mercedes Araceli, L. Fukushima-Díaz de León · 2010
  80. The role of gut hormones on food intake and carbohydrate tolerance
    George Tharakan · 2016 · Spiral (Imperial College London)
  81. Glucagon receptor family (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
    DOMINIQUE BATAILLE, Susan L.F. Chan, Philippe Delagrange, Daniel J. Drucker, Burkhard Göke, Rebecca Hills, Kelly E. Mayo, Laurence J. Miller, Roberto Salvatori, Bernard Thorens · 2019 · IUPHAR/BPS Guide to Pharmacology CITE
  82. Effect of Central GLP-1 on Gestric Mucosal Blood Flow; the Role of Specific Receptors
    Türkan ÇELİK, Naciye İŞBİL · 2019 · Turkiye Klinikleri Journal of Medical Sciences
  83. Glucagon receptor family in GtoPdb v.2021.3
    DOMINIQUE BATAILLE, Susan L.F. Chan, Philippe Delagrange, Daniel J. Drucker, Burkhard Göke, Rebecca Hills, Kelly E. Mayo, Laurence J. Miller, Roberto Salvatori, Bernard Thorens · 2021 · IUPHAR/BPS Guide to Pharmacology CITE
  84. The Role of GLP-1 Receptor Agonists in Diabetic Kidney Disease: Recent Evidence
    Jin Hwa Kim · 2025 · Journal of Korean Diabetes
  85. Drug Repurposing: Harnessing the Therapeutics from Antidiabetic Molecules
    Archana Bhatta, Priyanka Mahale, Harapriya Baral, D. K. Yuvaraj, Ravinder Kumar Kaundal · 2026 · Springer eBooks
  86. Adiponectin Signaling Dysfunction and Pro-inflammation in Perivascular Adipose Tissue in Non-obstructive Ischemic Heart Disease: A Narrative Literature Review of New Endocrine-Metabolic Therapeutic Targets
    Paulina Elizabeth Cisneros Clavijo, Diego Fernando Pinzon Tejada, John Manuel Dorado Ramírez, Sergio Daniel Zabaleta Orozco, Nataisha Michaella Seidlitz Arteaga, Adolfo Martínez Hernández, Diego Adolfo Vimos Congacha, Rodolfo Granados Villa · 2026 · Cureus
  87. The effects of metformin on metabolism and cardiovascular disease in type 2 diabetes
    Jolien de Jager · 2010